logo

COYA

Coya Therapeutics·NASDAQ
--
--(--)
--
--(--)
0.82 / 10
Underperform

COYA's fundamental rating is weak (0.8/10). Key concerns include negative asset-to-market value (-0.5007) and net income-to-revenue (-0.1668) differentials, both in the first performance group, signaling limited operational efficiency. Although year-over-year revenue growth is positive at 12.2081%, it is insufficient to counteract a negative net profit margin (-389.3257) and EBIT ratio (-3056.4269). Historical group analysis shows consistently negative one-month returns for these factors, reinforcing the cautionary outlook.

Fundamental(0.82)SentimentTechnical

Analysis Checks(1/10)

Revenue-MV
Value-1.66
Score1/3
Weight1.66%
1M Return-0.58%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight4.77%
1M Return-1.63%
Total operating revenue (YoY growth rate %)
Value12.21
Score0/3
Weight15.48%
1M Return-6.59%
Net cash flow from operating activities / Operating revenue (%)
Value-244.17
Score1/3
Weight5.20%
1M Return-2.03%
Net income-Revenue
Value-0.17
Score1/3
Weight2.13%
1M Return-0.69%
Net profit margin (%)
Value-389.33
Score0/3
Weight18.62%
1M Return-8.03%
Current assets turnover ratio
Value0.10
Score0/3
Weight14.51%
1M Return-7.31%
EBIT / Total operating revenue (%)
Value-3056.43
Score0/3
Weight17.61%
1M Return-7.44%
Asset-MV
Value-0.50
Score1/3
Weight1.77%
1M Return-0.51%
Net profit / Total operating revenue (%)
Value-389.33
Score0/3
Weight18.26%
1M Return-7.85%
Is COYA undervalued or overvalued?
  • COYA scores 0.82/10 on fundamentals and holds a Premium valuation at present. Backed by its -46.42% ROE, -462.25% net margin, -4.98 P/E ratio, 3.71 P/B ratio, and -70.77% earnings growth, these metrics solidify its Underperform investment rating.